The current system of funding in this country often precludes the ability of investigators to take chances on high risk research ideas. Our developmental research program was designed to fund pilot projects that emphasize new ideas and translational research from new as well as established investigators. Approximately $200,000 per year has been allocated for four to five pilot proposals. Approximately $25,000 per year has been allocated for student research proposals/stipends to attract undergraduate and graduate students to the field of translational prostate cancer research at the University of Michigan. Investigators are invited to submit proposals in the form of a five page proposal to the Executive Committee of the University of Michigan Comprehensive Cancer Center (UMCCC) Prostate SPORE through a University- wide announcement. Investigators with proposals which are translational in nature are then invited to make a presentation to the operating committee. The Operating Committee than rank proposals for funding based on scientific merit by secret ballot. Student projects are chosen by an abstract from the student and a letter of recommendation from their mentor. Investigators of all the submitted proposals are invited to take part in SPORE meetings and activities to promote dissemination of knowledge and promote interactions among investigators. Proposals chosen for funding are assign a basic science and clinical resource person from the Operating Committee to meet with on a regular basis to ensure that the translation goals of the Prostate SPORE are being met. Pilot project investigators present their research two times per year t the SPORE seminar series. Competition for these awards has been vigorous and we have been able to fund 20-30% of applications. To date, the UMCCC SPORE has funded 16 faculty development awards and 13 student awards. We believe that this developmental research program has been highly interactive between old and new investigators to the field of prostate cancer research and has simulated high risk translational projects. Two of the faculty development projects from the first two years of the SPORE grant have evolved into full projects and have been included in this application.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA069568-05
Application #
6203369
Study Section
Project Start
1999-08-09
Project End
2003-07-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
791277940
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rye, Morten Beck; Bertilsson, Helena; Andersen, Maria K et al. (2018) Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized. BMC Cancer 18:478
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Lin, Ke-Chih; Torga, Gonzalo; Wu, Amy et al. (2017) Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. Converg Sci Phys Oncol 3:
Piert, Morand; Montgomery, Jeffrey; Kunju, Lakshmi Priya et al. (2016) 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med 57:1065-70
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Mehra, Rohit; Udager, Aaron M; Ahearn, Thomas U et al. (2016) Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol 70:549-552

Showing the most recent 10 out of 527 publications